Skip to main content

James Crowe Jr.

Early study finds antibody that ‘neutralizes’ Zika virus

Nov. 7, 2016—Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

Read more


Investigators create ‘Trojan Horse’ to fight Ebola

Sep. 8, 2016—A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.

Read more


Research team takes aim at Ebola virus ‘decoy protein’

Aug. 11, 2016—Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.

Read more


Vanderbilt and Human Vaccines Project launch initial studies to decode the human immune system

Jun. 21, 2016—Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system.

Read more


Potent HIV antibodies suggest new vaccine development approach

Apr. 7, 2016—It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.

Read more


Vanderbilt researchers identify potential antibody treatment for H7 avian flu

Mar. 7, 2016—Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.

Read more


Antibodies may be ‘silver bullet’ for Ebola viruses

Jan. 21, 2016—There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.

Read more


Caucus explores crucial role of NIH research funding

Dec. 3, 2015—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL).

Read more


Two Ebola Survivors’ Blood Could Help Vanderbilt Researchers Find A Treatment

Oct. 19, 2015—Vanderbilt researchers could be one step closer to finding a way to fight the deadly Ebola virus – thanks to two Ebola victims from Nigeria, who faced death and survived. Vanderbilt researchers developed a unique method of isolating potent Ebola-fighting antibodies from survivors’ blood and they believe these newest potent antibody samples are an important...

Read more


Survivors of Ebola outbreak take part in VUMC vaccine study

Sep. 24, 2015—Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection.

Read more


Ebola symposium to feature Nigerian physicians

Sep. 10, 2015—Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16.

Read more


How to trick a wily virus

Jul. 24, 2015—Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.

Read more


VIEW MORE EVENTS >